14.25
-1.28 (-8.26%)
| Penutupan Terdahulu | 15.53 |
| Buka | 15.54 |
| Jumlah Dagangan | 38,319 |
| Purata Dagangan (3B) | 31,635 |
| Modal Pasaran | 153,424,000 |
| Harga / Jualan (P/S) | 3.21 |
| Harga / Buku (P/B) | 3.18 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Jun 2025 - 6 Jun 2025 |
| Margin Keuntungan | -45.59% |
| Margin Operasi (TTM) | -11.41% |
| EPS Cair (TTM) | -3.22 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.40% |
| Nisbah Semasa (MRQ) | 3.02 |
| Aliran Tunai Operasi (OCF TTM) | -75.58 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -7.97 M |
| Pulangan Atas Aset (ROA TTM) | -14.39% |
| Pulangan Atas Ekuiti (ROE TTM) | -37.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Bercampur |
| Diagnostics & Research (Global) | Menaik | Bercampur | |
| Stok | Burning Rock Biotech Limited | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.88 |
|
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| % Dimiliki oleh Orang Dalam | 3.92% |
| % Dimiliki oleh Institusi | 59.86% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| China Universal Asset Management Co., Ltd. | 30 Sep 2025 | 3,000 |
| Shen Neil Nanpeng | 30 Sep 2025 | 885 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 01 Dec 2025 | Pengumuman | Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025 |
| 20 Nov 2025 | Pengumuman | Burning Rock Reports Third Quarter 2025 Financial Results |
| 24 Sep 2025 | Pengumuman | Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer |
| 08 Sep 2025 | Pengumuman | Burning Rock Reports Second Quarter 2025 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |